Article
Gastroenterology & Hepatology
Robert C. Grant, Robert Denroche, Gun Ho Jang, Klaudia M. Nowak, Amy Zhang, Ayelet Borgida, Spring Holter, James T. Topham, Julie Wilson, Anna Dodd, Raymond Jang, Rebecca Prince, Joanna M. Karasinska, David F. Schaeffer, Yifan Wang, George Zogopoulos, Scott Berry, Diane Simeone, Daniel J. Renouf, Faiyaz Notta, Grainne O'Kane, Jennifer Knox, Sandra Fischer, Steven Gallinger
Summary: Patients with MMRD pancreatic cancer exhibit longer overall survival, distinct histopathological and genomic features, and may benefit from targeted therapies based on their unique genomic drivers.
Article
Oncology
Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa Affolter, Heloisa P. Soares, Chris Nevala-Plagemann, Courtney Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido-Laguna
Summary: Pure pancreatic acinar cell carcinomas (PACC) are rare malignancies with significant genetic intertumoral heterogeneity. Compared to pancreatic ductal adenocarcinomas (PDAC), PACC shows major molecular differences, including downregulation of the MAPK signaling pathway and less stromal cell abundance. Genomic characterization of pure PACC reveals frequent targetable alterations, providing potential guidance for patient treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Hao Xu, Lu Yin, Qianhui Xu, Jingjing Xiang, Rujun Xu
Summary: This study reveals the important role of m6A modification patterns in the diversity and complexity of the tumor immune microenvironment (TIME) in pancreatic adenocarcinoma (PAAD). The m6Ascore system can serve as an independent and powerful prognostic biomarker and is potentially related to immunotherapies for PAAD.
CANCER CELL INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Ziyang Liu, Anqiang Wang, Yingying Pu, Zhongwu Li, Ruidong Xue, Chong Zhang, Xiao Xiang, E. Jian-Yu, Zhaode Bu, Fan Bai, Jiafu Ji
Summary: Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer with high mortality rate. Research suggests that HAS may originate from pluripotent precursor cells and has high stemness and methionine cycle activity. Genes involved in the methionine cycle, such as MAT2A and AHCY, are potential targets for HAS treatment.
Review
Endocrinology & Metabolism
Praveen Dilip Chatani, Sunita Kishore Agarwal, Samira Mercedes Sadowski
Summary: PNETs are classified based on histologic differentiation and proliferative indices, with advances in high-throughput techniques allowing researchers to explore genetic alterations associated with malignant transformation. Clinical aggressiveness stratifies along other genotypic and phenotypic demarcations, impacting the potential molecular signatures, associated trials, and differences in responses to therapies for PNETs.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Oncology
Anna La Salvia, Irene Persano, Elena Parlagreco, Alessandro Audisio, Massimiliano Cani, Maria Pia Brizzi
Summary: Pancreatic adenocarcinoma is a common and aggressive type of pancreatic cancer with poor prognosis, while neuroendocrine neoplasms of the pancreas are generally considered less aggressive. However, high-grade neuroendocrine carcinoma has a particularly poor prognosis. Currently, there are no personalized therapies available for these conditions, and the quality of life for these patients is disappointing.
Article
Oncology
Sarah R. Kaslow, Gerardo A. Vitiello, Katherine Prendergast, Leena Hani, Steven M. Cohen, Christopher Wolfgang, Russell S. Berman, Ann Y. Lee, Camilo Correa-Gallego
Summary: This study assessed treatment patterns and outcomes for poorly differentiated pancreatic neuroendocrine carcinoma and found that surgical resection was strongly associated with improved overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Hyung Kyu Park, Ghee Young Kwon
Summary: This study compared the metastatic patterns of neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and non-neuroendocrine neoplasms (non-NENs), and found significant differences between NETs/NECs and non-NENs. The key factor causing these differences may be associated with the multigene program of neuroendocrine differentiation.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Article
Biochemistry & Molecular Biology
Sangyeop Hyun, Daechan Park
Summary: In this review, the current status of research on pancreatic ductal adenocarcinoma was introduced, highlighting how genomic studies have provided new avenues for pancreatic cancer treatment, and discussing the differences between model systems and primary tumors.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Oncology
Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Maria Isabel Lumbreras-Herrera, Rocio Lopez-Vacas, Victoria Heredia-Soto, Ismael Ghanem, Elena Lopez-Camacho, Andrea Zapater-Moros, Maria Miguel, Eva M. Pena-Burgos, Elena Palacios, Marta De Uribe, Laura Guerra, Antje Dittmann, Marta Mendiola, Juan Angel Fresno Vara, Jaime Feliu
Summary: Pancreatic cancer is an aggressive disease with a high mortality rate. A study identified three proteomic tumor subtypes (adhesion subtype, metabolic subtype, and nucleoplasm subtype) in pancreatic tumors, each with differences in carcinogenesis and tumor progression mechanisms. Understanding these differences may lead to tailored therapeutic approaches for each subtype.
Article
Biotechnology & Applied Microbiology
Junfei Chen, Yongjie Wang, Hua Jiang
Summary: This study investigates the metabolic landscape of pancreatic ductal adenocarcinoma (PDAC) using bioinformatics analysis. Three subtypes of PDAC with distinct metabolic patterns and clinical characteristics were identified. Moreover, a gene classifier was developed for accurate prediction of prognosis and treatment response in PDAC.
CANCER GENE THERAPY
(2023)
Article
Oncology
Gokce Askan, Ibrahim Halil Sahin, Joanne F. Chou, Aslihan Yavas, Marinela Capanu, Christine A. Iacobuzio-Donahue, Olca Basturk, Eileen M. O'Reilly
Summary: The study found that the expression of CD44 and ESA in PDAC patients is related to tumor stroma type, and tumor stroma may influence recurrence patterns, but there was no significant difference among subgroups in terms of RFS and OS.
Article
Oncology
Jiahong Jiang, Yaping Xu, Lianpeng Chang, Guoqing Ru, Xuefeng Xia, Ling Yang, Xin Yi, Zheling Chen, Dong-Sheng Huang, Liu Yang
Summary: This study revealed the presence of driver gene mutations in PDAC stroma, indicating that the genomic features of stromal components may serve as prognostic biomarkers in resectable PDAC and may help guide a more precise treatment paradigm in therapeutic options.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Sarah E. Umetsu, Sanjay Kakar, Olca Basturk, Grace E. Kim, Deyali Chatterjee, Kwun Wah Wen, Gillian Hale, Na fis Sha, Soo-Jin Cho, Julia Whitman, Ryan M. Gill, Kirk D. Jones, Pooja Navale, Emily Bergsland, David Klimstra, Nancy M. Joseph
Summary: Distinguishing between grade 3 pancreatic neuroendocrine tumor (G3 PanNET) and neuroendocrine carcinoma (PanNEC) is a known diagnostic challenge. In this study, 47 high-grade neoplasms were reviewed, and molecular profiling was performed to improve diagnostic accuracy. The study found that molecular profiling and immunohistochemistry greatly improved the classification of high-grade pancreatic neuroendocrine neoplasms. Rating: 8/10.
Review
Biochemistry & Molecular Biology
Shirin Hafezi, Maha Saber-Ayad, Wael M. Abdel-Rahman
Summary: The RAS gene family, especially KRAS, is the most frequently mutated oncogene family in human cancer history, with a significant impact on pancreatic cancer progression. Studying the function of KRAS and its mutations in the tumor microenvironment is crucial for understanding pancreatic cancer and developing novel therapeutic strategies.ongoing clinical trials are using the KRAS oncogene signaling network as therapeutic targets, in addition to exploring the link between diabetes and PDAC, and the potential role of vitamin D in TME modulation for the treatment of PDAC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)